|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients显示文摘AIM:To investigate the efficacy and safety of capecitabine plus irinotecan±bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated,locally-advanced or metastatic colorectal cancer(mCRC) were recruited between 2001-2006 in a prospective open-label phaseⅡtrial,in German community-based outpatient clinics.Patients received a standard capecitabine plus irinotecan(CAPIRI) or CAPIRI plus bevacizumab(CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of>grade 2 toxicity.The treatment choice of bevacizumab was at the discretion of the physician.Theprimary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS:In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients(47% vs 24%) ,and more patients had colon as the primary tumor site(58.8%vs 48.2%) with fewer patients having sigmoid colon as primary tumor site(5.9%vs 20.7%) .Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev:82%vs 58.6%.Partial response rates were 29.4%and 34.5%,and tumor control rates were 70.6%and 75.9%,respectively.No complete responses were observed.The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev,respectively.The median overall survival for CAPIRI was 15 mo(458 d) and for CAPIRI-Bev 24 mo(733 d) .These differences were not statistically different.In the CAPIRI-Bev,group,two patients underwent a full secondary tumor resection after treatment,whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION:Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting.Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal. | Markus Moehler Martin F Sprinzl Murad Abdelfattah Carl C Schimanski Bernd Adami Werner Godderz Klaus Majer Dimitri Flieger Andreas Teufel Juergen Siebler Thomas Hoehler Peter R Galle Stephan Kanzler | 2009 | World Journal of Gastroenterology2009，15，4： | 10 |
| 2 | 急性缺血性卒中的机械取栓治疗:ESO、ESMINT、ESNR和EAN共同支持的2014/2015 ESO-卡罗林斯卡卒中更新会议共识声明显示文摘这份卒中后机械取栓治疗共识声明的原始版本于2014年11月16—18日在斯德哥尔摩召开的欧洲卒中组织(European Stroke Organisation, ESO)-卡罗林斯卡卒中更新会议期间得到批准。根据会议安排,在2015年利用新的临床试验数据对该声明进行了更新。2015年2月,在瑞士伯尔尼召开的ESO冬季培训会期间组织了面对面会议对共识声明进行修订,然后通过电子邮件交换意见,最终版本得到各学会的认可。推荐意见与原始版本一致,证据等级更新到2015年2月20日为止,在2015年5月15日获得确认。ESO-卡罗林斯卡卒中更新会议的目的在于总结卒中治疗研究的最新进展并探讨如何将这些最新研究结果应用于临床实践。共识会议选择了一些议题进行讨论,与会者草拟一份共识声明并进行讨论。该声明接受了ESO指南委员会的指导。这份共识声明包括对急性卒中后机械取栓治疗的推荐意见,得到欧洲卒中组织ESO、欧洲神经微创治疗学会(European Society of Minimally Invasive Neurological Therapy, ESMINT)、欧洲神经放射学学会(European Society of Neuroradiology, ESNR)和欧洲神经病学学会(European Academy of Neurology, EAN)的支持。 | Nils Wahlgren Tiago Moreira Patrik Michel Thorsten Steiner Olav Jansen Christophe Cognard Heinrich P Mattle Wim van Zwam Staffan Holmin Turgut Tatlisumak Jesper Petersson Valeria Caso Werner Hacke Mikael Mazighi Marcel Arnold Urs Fischer Istvan Szikora Laurent Pierot Jens Fiehler Jan Gralla Franz Fazekas Kennedy R Lees 高洁 徐格林 | 2016 | 国际脑血管病杂志2016，24，1： | 5 |
| 3 | Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial显示文摘 | Claus R?del Torsten Liersch Heinz Becker Rainer Fietkau Werner Hohenberger Torsten Hothorn Ullrich Graeven Dirk Arnold Marga Lang-Welzenbach Hans-Rudolf Raab Heiko Sülberg Christian Wittekind Sergej Potapov Ludger Staib Clemens Hess Karin Weigang-K?hler G | 2012 | Lancet Oncology2012，，7： | 2 |
| 4 | Scenario Reduction Algorithms in Stochastic Programming显示文摘 | Holger Heitsch Werner R?misch | 2003 | Computational Optimization and Applications (-)2003，，2： | 2 |
| 5 | Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12显示文摘AIM To gather data on the antiviral efficacy and safety of second generation direct acting antiviral(DAA) treatment with respect to sustained virological response(SVR) 12 wk after conclusion of treatment, and to determine predictors of SVR12 in this setting.METHODS Two hundred and sixty patients treated with SOF combination partners PR(n = 51), R(n = 10), SMV(n = 30), DCV(n = 81), LDV(n = 73), or 3D(n = 15).144/260 were pre-treated, 89/260 had liver cirrhosis, 56/260 had portal hypertension with platelets < 100/nL, 25/260 had a MELD score ≥ 10 and 17/260 were postliver transplantation patients. 194/260 had HCV GT1, 44/260 HCV GT3.RESULTS Two hundred and forty/256(93.7%) patients achieved SVR12(m ITT); 4/260 were lost to follow-up. SVR12 rates for subgroups were: 92% for SOF/DCV, 93% for each SOF/SMV, SOF/PR, 94% for SOF/LDV, 100% for 3D, 94% for pretreated, 87% for liver cirrhosis, 82% for patients with platelets < 100/n L, 88% post-liver transplantation, 95% for GT1 a, 93% for GT1 b, 90% for GT3, 100% for GT2, 4, and 6. 12 patients suffered from relapse, 6 prematurely discontinued treatment, of which 4 died. Negative predictors of SVR12 were a platelet count < 100/nL, MELD score ≥ 10(P < 0.0001), liver cirrhosis(P = 0.005) at baseline. In Interferonfree treatment GT3 had significantly lower SVR rates than GT1(P = 0.016). Side effects were mild. CONCLUSION Excellent SVR12 rates and the favorable side-effect profile of DAA-combination therapy can be well translated into 'real-world'. Patients with advanced liver disease, signs of portal hypertension, especially with platelets < 100/n L and patients with GT3 are in special need for further research efforts to overcome comparatively higher rates of virological failure. | Christoph R Werner Julia M Schwarz Daniel P Egetemeyr Robert Beck Nisar P Malek Ulrich M Lauer Christoph P Berg | 2016 | World Journal of Gastroenterology2016，22，35： | 2 |
| 6 | Does the stock market overreact显示文摘 | Bondt De Werner F M Thaler R H | 1985 | Journal of Finance1985，40，3： | 2 |
| 7 | Further evidence on investor overreaction and stock market seasonality显示文摘 | Bondt De Werner F M Thaler R H | 1987 | Journal of Finance1987，42，3： | 2 |
| 8 | Peroral Endoscopic Myotomy for the Treatment of Achalasia: An International Prospective Multicenter Study显示文摘 | Daniel Von Renteln Karl–Hermann Fuchs Paul Fockens Peter Bauerfeind Melina C. Vassiliou Yuki B. Werner Gerald Fried Wolfram Breithaupt Henriette Heinrich Albert J. Bredenoord Jan F. Kersten Tessa Verlaan Michael Trevisonno Thomas R?sch | 2013 | Gastroenterology2013，，2： | 2 |
| 9 | Two-dimensional phase unwrapping显示文摘 | Goldstein R M Zebker H A Werner C L | 1988 | Radio Sci1988，23，4： | 1 |
| 10 | Fractal antenna engineering: The theory and design of fractal antenna arrays显示文摘 | WERNER D H HAUPT R L WERNER P L | 1999 | IEEE Antennas Propagat Mag1999，41，5： | 1 |
| 11 | Characterization and identification of eytoehrome P450 metabolites of arachidonic acid released by human peritoneal maerophages obtained from the pouch of Douglas显示文摘 | Werner K Schaefer W R Schweer H | 2002 | Prastaglandins Leukot Essent Fatty Acids2002，67，6： | 1 |
| 12 | Regulation of wound healing by growth factors and cytokines显示文摘 | Werner S Grose R | 2003 | Physiol Rev2003，83，3： | 1 |
| 13 | SOX4,(prognostic ) marker for the aggressiveness of neuroendo-crine tumors of the lung by using next-generation expres-sion analysis (NanoString) 显示文摘 | Walter RF Mairinger FD Werner R | 2015 | Future Oncol2015，11，： | 1 |
| 14 | A positive geno-type-phenotype correlation in a large cohort of patientswith Pseudohypoparathyroidism Type Ia and Pseudo-pseudohypoparathyroidism and 33 newly identified muta-tions in the GNAS gene显示文摘 | Thiele S Werner R Grotzinger J | 2015 | Mol Genet Genomic Med2015，3，2： | 1 |
| 15 | Radiation characteristics of thin-wire ternary fractal trees 显示文摘 | Werner D H Rubio B A Long B R | 1996 | Electronics Letters1996，35，8： | 1 |
| 16 | Quantitative determination of physical and chemical measurands in honey by near-infrared spectrometry显示文摘 | Kaspar R Werner L Stefan B | 2007 | Europe Food Res earc h Technology2007，225，： | 1 |
| 17 | Functionalcharacterization of GNAS mutations found in patientswith pseudohypoparathyroidism type Ic defines a newsubgroup of pseudohypoparathyroidism affecting Gsα-receptor interaction显示文摘 | Thiele S de Sanctis L Werner R | 2011 | Hum Mutat2011，32，6： | 1 |
| 18 | Effects of saline,mannitol,and furosemide to prevent acute decreases in renal function induced by radiocontrast agents显示文摘 | Solomon R Werner C Mann D | 1994 | N Engl J Med1994，331，21： | 1 |
| 19 | Chemotaxis and nod gene activity of bradyrhizobium japonicum in response to hydroxy- cinnamic acids and isoflavonoids 显示文摘 | Kape R Parniske M Werner D | 1991 | Appl Environ Microbiol1991，57，： | 1 |
| 20 | A clinical evaluation of controlled-release dinoprostone for cervical ripening a review of current evidence in hospital and outpatient settings 显示文摘 | WERNER R | 2005 | J Perinat Med2005，33，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员